CD163 and neoplasm: Increasing clinical evidence has suggested that analyses of tumor immune environment (TIME) of treatment-naïve tumor has allowed for identifying components of immune contexture that are beneficial [including tumor-infiltrating lymphocytes (TILs): CD8+ cytotoxic cells, and CD3+ T cells] or deleterious (including Foxp3+ T cells, and CD163+ macrophages) to ovarian cancer patients (9–12).